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Introduction: Granulocyte colony-stimulating factor produced by nonhematopoietic malignant cells is able to induce
a leukemoid reaction by excessive stimulation of leukocyte production. Expression of granulocyte colony-stimulating
factor and its functional receptors have been confirmed in bladder cancer cells. In vitro studies have demonstrated
that granulocyte colony-stimulating factor/receptor exhibits a high affinity binding and this biological axis increases
proliferation of the carcinoma. Urothelial carcinoma of the bladder is rarely associated with a leukemoid reaction and
autocrine growth induced by paraneoplastic production of granulocyte colony-stimulating factor. In the world literature,
there have been less than 35 cases reported in the last 35 years. The clinicopathological aspects, biology, prognosis
and management of granulocyte colony-stimulating factor-secreting bladder cancers are poorly understood.
Case presentation: A 39-year-old Caucasian woman with an invasive high-grade urothelial carcinoma presented with
hematuria and low-grade fevers. Laboratory tests revealed an elevated white blood cell count and absolute neutrophil
count and an elevated 24-hour urine protein. Upon further evaluation she was found to have locally advanced
high-grade urothelial carcinoma without nodal or distant metastasis. Her serum granulocyte colony-stimulating
factor level was 10 times the normal limit. This led to the diagnosis of a paraneoplastic leukemoid reaction. Her white
blood cell count immediately normalized after cystectomy but increased in concordance with recurrence of her
disease. Unfortunately, she rapidly progressed and expired within 10 months from the time of first diagnosis.
Conclusions: This is one of the few cases reported that illustrates the existence of a distinct and highly aggressive
subtype of bladder cancer which secretes granulocyte colony-stimulating factor. Patients presenting with a leukemoid
reaction should be tested for granulocyte colony-stimulating factor/receptor biological axis. Moreover, granulocyte
colony-stimulating factor could be a potential neoplastic marker as it can follow the clinical course of the underlying
tumor and thus be useful for monitoring its evolution. Neoadjuvant chemotherapy should be considered in these
patients due to the aggressive nature of these tumors. With a better understanding of the biology, this autocrine
growth signal could be a potential target for therapy in future.
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C-reactive protein (mg/dL) 29.5 6.89
Antineutrophilic antibody 320 <80
24-hour urine protein (g) 14.65 5.25
Serum creatinine (mg/dL) 3.27 1.30
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Paraneoplastic leukemoid reaction is a type of paraneo-
plastic syndrome in which there is an elevation in the
white blood cell count, predominantly neutrophils. Gran-
ulocyte colony-stimulating factor (G-CSF) secreted by
nonhematopoietic malignant cells has been reported to be
able to induce a leukemoid reaction through excessive
stimulation of leukocyte production [1-3]. Urothelial
carcinoma of the bladder is rarely associated with a
leukemoid reaction, with less than 30 cases reported
over the past 30 years, some of which tried to elucidate
the role of G-CSF [1,3-7]. A previous study reported that
9.2% of bladder tumors are associated with high levels
of G-CSF [8]. In addition, expression of G-CSF and
functional G-CSF receptors (G-CSFR) has been demon-
strated in bladder cancer cells [9]. In vitro studies have
demonstrated that G-CSF/G-CSFR exhibit high affinity
[1] binding and this biological axis increases proliferation
in bladder cancer cells [1,9-11]. This autocrine mechanism
of growth may be associated with aggressive tumor growth
and adverse clinical outcomes [1,12]. Here, we present a
rare case of a leukemoid reaction and autocrine growth of
bladder cancer induced by paraneoplastic production of
G-CSF. We review the literature on the main clinicopath-
ological aspects of this important, but rare, condition and
review the biology of G-CSF in bladder cancer and its
implications for diagnosis, management, prognosis and
future research.
Case presentation
A 39-year-old non-cigarette-smoking Caucasian woman
with hypertension, type 2 diabetes, diabetic retinopathy
and neuropathy was diagnosed with muscle invasive high-
grade urothelial carcinoma with squamous and glandular
differentiation and necrosis by transurethral resection
of her bladder tumor 4 months prior to presentation to
our hospital. Three weeks prior to presentation in our
clinic she had noted gross hematuria, daily low-grade
fevers, night sweats and weight gain of 32kg. A physical
examination revealed that her temperature was 39°C
(102.2°F), pulse 110 per minute, respiratory rate 20 per
minute, and blood pressure 150/83mmHg. Her examin-
ation was only remarkable for progressive anasarca.
Laboratory studies revealed elevated white blood cell
(WBC) count and absolute neutrophil count (ANC; peak
WBC 57.8K/UL, peak ANC 43.24K/UL), leukocyte alkaline
phosphatase score 295, erythrocyte sedimentation rate
(ESR) >140mm/hour, C-reactive protein (CRP) 29.5mg/dL,
and antineutrophilic antibody (ANA) titer 320. She also
had nephrotic range proteinuria with 24-hour urine protein
of 14.65g and a serum creatinine of 3.27mg/dL (Table 1
and Figure 1). On admission, her urine grew greater than
100,000 Aerococcus urinae for which she was treated with a
course of ceftriaxone. Repeat urine and blood cultures werenegative but she had continued elevation of her WBC
count. The results of anti-double stranded deoxyribonucleic
acid (DNA) antibody, rheumatic factor, anti-SSA, anti-SSB,
anti-glomerular basement membrane, myeloperoxidase,
proteinase 3, cytoplasmic antineutrophil cytoplasmic anti-
body, perinuclear antineutrophil cytoplasmic antibody,
hepatitis panel, and human immunodeficiency virus anti-
body tests were negative. Serum protein electrophoresis,
creatine phosphokinase, quantitative immunoglobulin assay,
complement levels and chest radiograph were all normal.
Hence, symptoms, signs and laboratory studies were
negative for an infectious etiology (including a tagged
WBC scan) and autoimmune/rheumatological disease.
A bone scan and positron emission tomography scan
ruled out metastasis (Figure 2). A computed tomography
(CT) scan showed a large nodular bladder mass (Figure 3).
The fevers and night sweats were attributable to her
malignancy and her weight gain/anasarca was related to
her nephrotic syndrome. After her medical condition was
optimized, she underwent a radical cystectomy, bilateral
pelvic lymph node dissection, and ileal conduit urinary di-
version along with total abdominal hysterectomy/bilateral
salpingo-oophorectomy. Immediately after removal of her
bladder tumor, her presenting symptoms and laboratory
values improved remarkably. Fevers and night sweats
completely resolved. Her WBC count was 6.8K/UL, ANC
5.05K/UL, ESR 45mm/hour, CRP 6.89mg/dL, ANA <80,
24-hours urine proteins of 5.25g, and serum creatinine
1.30mg/dL (Table 1). Histopathology revealed poorly dif-
ferentiated high-grade transitional cell carcinoma invading
the entire bladder wall and the myometrium of the lower
uterine segment along with vascular invasion without
metastasis. Her pathologic staging was pT4a,N0,M0
(Figure 4). In addition, to further evaluate her nephrotic
syndrome, a renal ultrasound-guided biopsy was done.
Her kidneys were of normal size. The biopsy showed
diabetic nephropathy with extensive nodular glomeruli
sclerosis, moderate interstitial fibrosis and mild focal
Figure 1 Graphical representation of the trend of white blood cell counts before and after cystectomy (see arrow). X axis represents
time and Y axis represents white blood cell count in K/UL. Green and blue lines represent the normal range of white blood cell count. Pink line
represents the trend in the patient’s white blood cell count.
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arteriolar hyalinosis. She responded to hemodialysis and
her serum creatinine trended down to 1.30mg/dL with
resolution of anasarca.
The patient refused adjuvant chemotherapy and returned
3 months following her cystectomy with an elevated
WBC (peak WBC 45.3K/UL) and serum creatinine 1.90.
A CT scan showed multiple pelvic masses with abdominal
lymphadenopathy and a large right pelvic mass in close
approximation to the area of the sigmoid colon causing
obstruction. Her serum G-CSF level was 406.6pg/mL
(normal <39.1pg/mL) confirming the diagnosis of para-
neoplastic leukemoid reaction. She underwent a diverting
colostomy to relieve symptoms of bowel obstruction.
However due to poor performance status, renal failure
and the development of a colovaginal fistula, she was
placed on palliative care and expired soon thereafter.
Discussion
This rare case of urothelial carcinoma of the bladder had
several unusual features including young age at presenta-
tion, marked leukemoid reaction, elevated G-CSF levels
(ten times the normal limit), nephrotic range proteinuria
and very rapid progression of disease to death within 6
months of the onset of the leukemoid reaction. Urothelial
carcinoma in this case showed squamous differentiation
which has been reported to have elevated G-CSF levels
[4-6]. A possible mechanism for development of leuke-
moid reaction and rapid metastatic spread of the tumor
is that the high-grade urothelial carcinoma harboredboth paraneoplastic production of G-CSF and expression
of functional G-CSFR. This may have stimulated the bone
marrow with increased myelopoiesis and leukemoid reac-
tion. The stimulation of tumor growth may have been due
to the expression of functional G-CSFR by the neoplastic
cells, creating a positive feedback cycle. This mechanism
has been demonstrated in in vitro studies [1,9,11]. Con-
sistent with this mechanism, the above unusual features
normalized after removal of the tumor (Table 1 and
Figure 1). Similar post-surgical normalization of the
leukemoid reaction and G-CSF has been previously
observed in bladder cancer [5,13]. Three months later, with
recurrence of tumor, there was elevated WBC and G-CSF.
Hence, G-CSF could be used to follow the evolution of
cancer and as a potential future prognostic marker. Of
note, this case also exhibited nephrotic range proteinuria
which improved after tumor removal, thereby clinically
seemed to be paraneoplastic, but biopsy showed features
of diabetic nephropathy. Minimal-change glomerulopathy
associated with urothelial carcinoma has been rarely re-
ported in the literature [14,15]. However, this may have
been masked by her pre-existing diabetic nephropathy.
In the present case, as the tumor recurred and grew in
her pelvic cavity, the concentration of serum G-CSF was
elevated with an associated increase in her WBC count.
These findings support the hypothesis that the bladder
cancer cells producing G-CSF may grow more rapidly or
that the G-CSF production exhibited by the tumor cells
may promote the malignant progression. We thus under-
took a comprehensive review of all studies and similar
Figure 3 Computed tomography scan of the pelvis showing large
nodular bladder mass with heterogeneous enhancement, prior to
cystectomy. Exchange are most extensive along the right bladder wall
though is also seen along the left bladder wall and fundus.
Figure 4 Histological examination of the cystectomy specimen
showing poorly differentiated high-grade transitional cell carcinoma.
(Hematoxylin and eosin section, original magnification×220).
Figure 2 Positron emission tomography scan showing metabolic
activity only in the bladder, prior to cystectomy. There is no
evidence of regional or distant metastasis. There is slight increased
activity in the skeletal system which is probably secondary to a marrow
stenting agent.
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It is also probable that the patient had micrometastatic
disease, undetectable by currently existing diagnostic mo-
dalities, prior to surgery. Rapid development of metastases
within 3 months after surgery may have been invigorated
by G-CSF secretion and activation of the G-CSF/G-CSFR
biological axis stimulating tumor growth.
A review by Turalic et al. showed that the average age
of these patients was 70.1 years and the male to female
ratio was 3:2. The WBC was as high as 181,800/mL
(average 66,758/mL) and there was an average G-CSF
level of 203pg/mL with a mean survival of 5.9 months
following surgical therapy in these patients. However,
those who received adjuvant chemotherapy reported
survivals of >20 months [4]. An observational study in
Japanese patients by Mizutani et al. in 1995 showed
that 9.2% of bladder tumors had elevated G-CSF levels
(mean G-CSF of 328), which positively correlated with
an increase in grade and progression of stage of cancer,
more so in patients with distant metastasis. Furthermore,
patients with bladder cancer without elevated G-CSF had
better disease-specific survival rates at 5 years follow-up
when compared with those with an elevated level of serum
G-CSF [8].
The mechanism responsible for overexpression of G-
CSF in bladder cancer is yet to be clearly elucidated.
Possibilities include rearrangement of the G-CSF gene
occurring within one of the alleles [16] and intrinsic
activation of nuclear factors that work on the promoter
region of the G-CSF gene [17]. Treatment with phorbol
ester, interleukin-1 beta, or interferon gamma increased
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stimulating factor, and macrophage colony-stimulating
factor in an in vitro bladder cancer cell line study. This
capability to respond to various stimuli implies that
numerous regulatory pathways may be involved in the
production of cytokines [18]. Although the mechanism of
G-CSF gene overexpression requires further investigation,
Chakraborty et al. conducted a series of in vitro studies
which have shown that G-CSFR specifically signals for
beta-1 integrin expression, adhesion and invasion of
bladder cancer cells which could promote metastasis
[19]. Furthermore, they demonstrated that the G-CSF/
G-CSFR biological axis facilitated survival and growth
of bladder cancer cells and stimulated STAT3-dependent
survivin expression [11]. The histogenesis of transitional
cell carcinoma of the bladder is uncertain, although differ-
ent theories have been proposed. Some authors have
suggested that a metaplastic phenomenon with various
degrees of differentiation may be responsible for the
malignant transitional cell G-CSF production [20]. In
addition, this theory is supported further by the remarkable
potential of the transitional epithelium and transitional
cell carcinoma to differentiate into several lines [21].
The frequent finding of both squamous and glandular
differentiation has long been observed in transitional
cell carcinoma. Furthermore, the presence of neuroendo-
crine (small cell) differentiation has also been reported [22].
Hematopoietic differentiation of transitional cell carcinoma,
resulting in the acquirement of G-CSF production and
G-CSFR expression, is another possibility supported by
our observations. Lastly, G-CSF may be released from
the foci of tumor necrosis [7]. Hence, G-CSF could be a
potential screening tool to predict aggressive cancer and
hence pursue an early aggressive treatment modality.
G-CSF administration has been in vogue as an adjunct
to the management of granulocytopenias, either with or
without prior chemotherapy [23-26]. Subsequent studies
have further confirmed the efficacy of G-CSF in con-
junction with systemic chemotherapy for patients with
advanced bladder cancer [27,28]. A few studies recommend
G-CSF administration to enhance the tumor-specific
cytotoxicity of chemotherapy [29,30], to allow dose
intensification of chemotherapy [31-33] with low mye-
lotoxicity and mucosal toxicity levels [31]. In contrast,
Perez et al. reported a case of rapid clinical deterioration
and leukemoid reaction after treatment of urothelial
carcinoma with G-CSF along with chemotherapy [7].
Recombinant G-CSF may have both direct and indirect
stimulatory effects on the growth of bladder cancer
cells in vitro. It may stimulate the growth of the residual
tumor cells after chemotherapy while it is being used
clinically to combat myelosuppression induced by anti-
tumor chemotherapy in bladder cancer [34]. Due to
controversial reports, at this time, we can only advocatethat all bladder cancers should be tested for the expression
of G-CSFR before using G-CSF, because there is the
possibility of growth stimulation by G-CSF if they have
G-CSFR on their cell surfaces. With a better understand-
ing of the biology, this autocrine growth signal could be a
potential target for therapy in future.
Conclusions
On the basis of this case experience and review of literature
we conclude that there is a distinct and highly aggressive
subtype of bladder cancer which secretes G-CSF and
expresses G-CSFR inducing an autocrine growth cycle.
Hence such patients presenting with leukemoid reaction
should be tested for G-CSF/G-CSFR biological axis. More-
over, G-CSF could be a potential neoplastic marker as it
can follow the clinical course of the underlying tumor and
thus be useful for monitoring its evolution. Neoadjuvant
chemotherapy should be considered as the aggressive
nature of these tumors appears to overwhelm these patients
before they receive adjuvant treatments. With a better
understanding of the biology, this autocrine growth signal
could be a potential target for therapy in future.
We are currently planning to conduct a preliminary
study to identify patients with such bladder cancer, not
only to estimate its prevalence but also to assess the
variation in G-CSF levels in response to various therapies
(surgery, chemotherapy, radiotherapy). In addition we
will evaluate G-CSF as a prognostic marker and as a
tool to predict a more aggressive biological phenotype
of invasive bladder cancer. Future studies will be necessary
to determine the regulatory effects of G-CSF on bladder
cancer cells.
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